Dotz Nano Limited (ASX:DTZ) an advanced technology company developing, manufacturing and commercialising tagging, tracing and verification solutions, is engaging with the medical industry and academic leaders to progress the possible use of its products in biomedical applications.
This strategic focus entails Dotz’s anti-counterfeiting solutions for plastic medical devices and new applications derived from this breakthrough research conducted by five university and research facilities including Rice University. It was demonstrated that GQDs can assist in fighting oxidative stress to assist in treating patients suffering from a range of serious conditions including brain injuries, strokes, MS and heart attacks. Dotz’s scientific advisor Professor James Tour led the study, which is now widely covered by medical publications.
Dotz holds the exclusive license for manufacturing of GQDs from coal, and the company has reached commercial production capacity, which now allows engagement with the medical industry to explore possible commercialisation.
Dr. Yoni Engel, Dotz’s director of product development, said: “Carbon-based nanomaterials are known to be excellent scavengers of reactive oxygen species, or ‘free radicals’, which are often a contributing factor for stroke, cardiovascular disease and cancer.
“However, issues such as cytotoxicity and the ability to manufacture carbon-based nanomaterials in an efficient and reproducible manner have previously prevented their successful use in the market. The research by Rice University and its research partners demonstrates that coal-based low toxicity GQDs can be successfully used to uncover diseases and fight oxidative stress in living mice. These latest results, combined with Dotz’s commercial production capacities, provides great opportunities for GQDs in various medical applications that can be explored in later research and possibly treatments.”
Dotz CEO Uzi Breier, said: “Dotz is actively seeking commercial partnership opportunities within the medical market for both our biomedical and anti-counterfeiting technologies. This new study highlights the promising effect of GQDs in treating a range of serious medical conditions and Dotz has the manufacturing capability to cost-effectively cater to future commercial requirements.”
